SG11202111720TA - Mrna formulation - Google Patents

Mrna formulation

Info

Publication number
SG11202111720TA
SG11202111720TA SG11202111720TA SG11202111720TA SG11202111720TA SG 11202111720T A SG11202111720T A SG 11202111720TA SG 11202111720T A SG11202111720T A SG 11202111720TA SG 11202111720T A SG11202111720T A SG 11202111720TA SG 11202111720T A SG11202111720T A SG 11202111720TA
Authority
SG
Singapore
Prior art keywords
mrna
pseudouridine
anyone
thio
combination
Prior art date
Application number
SG11202111720TA
Other languages
English (en)
Inventor
Koker Stefaan De
Sanne Bevers
Peter Tomme
Original Assignee
Etherna Immunotherapies Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Etherna Immunotherapies Nv filed Critical Etherna Immunotherapies Nv
Publication of SG11202111720TA publication Critical patent/SG11202111720TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202111720TA 2019-04-26 2020-04-24 Mrna formulation SG11202111720TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19171323 2019-04-26
PCT/EP2020/061477 WO2020216911A1 (en) 2019-04-26 2020-04-24 Mrna formulation

Publications (1)

Publication Number Publication Date
SG11202111720TA true SG11202111720TA (en) 2021-11-29

Family

ID=66290283

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111720TA SG11202111720TA (en) 2019-04-26 2020-04-24 Mrna formulation

Country Status (12)

Country Link
US (1) US20220362360A1 (cg-RX-API-DMAC7.html)
EP (1) EP3958893A1 (cg-RX-API-DMAC7.html)
JP (1) JP7650001B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220023340A (cg-RX-API-DMAC7.html)
CN (1) CN114096272B (cg-RX-API-DMAC7.html)
AU (1) AU2020263948B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021262A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138011A1 (cg-RX-API-DMAC7.html)
IL (1) IL287560B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021013018A (cg-RX-API-DMAC7.html)
SG (1) SG11202111720TA (cg-RX-API-DMAC7.html)
WO (1) WO2020216911A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7496623B2 (ja) * 2019-01-04 2024-06-07 イーザアールエヌーエー イムノセラピーズ エンヴェー mRNAワクチン
US20220143161A1 (en) * 2019-03-13 2022-05-12 Etherna Immunotherapies Nv Mrna vaccine
CN119701015A (zh) * 2023-09-26 2025-03-28 深圳瑞吉生物科技有限公司 一种细胞因子mRNA组合药物及其应用
CN121873266A (zh) * 2026-03-18 2026-04-17 北京悦康科创医药科技股份有限公司 一种增强肿瘤疫苗免疫原性的嵌合多肽及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2201100E (pt) * 2007-09-14 2016-06-03 Univ Brussel Vrije Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
US9408909B2 (en) * 2007-09-14 2016-08-09 Vrije Universiteit Brussel Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
EP3173474A1 (en) * 2007-09-14 2017-05-31 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2015071295A1 (en) 2013-11-12 2015-05-21 Vrije Universiteit Brussel Rna transcription vector and uses thereof
DK4276189T3 (da) * 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes

Also Published As

Publication number Publication date
BR112021021262A2 (pt) 2021-12-21
AU2020263948B2 (en) 2026-06-25
CN114096272B (zh) 2024-08-06
EP3958893A1 (en) 2022-03-02
CN114096272A (zh) 2022-02-25
WO2020216911A1 (en) 2020-10-29
JP7650001B2 (ja) 2025-03-24
IL287560B2 (en) 2026-02-01
US20220362360A1 (en) 2022-11-17
AU2020263948A1 (en) 2021-12-23
MX2021013018A (es) 2022-03-11
CA3138011A1 (en) 2020-10-29
IL287560B1 (en) 2025-10-01
JP2022532038A (ja) 2022-07-13
KR20220023340A (ko) 2022-03-02
IL287560A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
US20240325522A1 (en) Rna adsorbed onto lipid nano-emulsion particles and its formulations
US20220362360A1 (en) Mrna formulation
KR20160055863A (ko) 면역 부활 활성을 갖는 올리고뉴클레오티드 함유 복합체 및 그 용도
US12084703B2 (en) Synthetic self-amplifying mRNA molecules with secretion antigen and immunomodulator
CN119110847A (zh) 针对sars-cov-2变体的环状rna疫苗及其使用方法
CN115845043B (zh) 一种模板DNA分子及其在制备mRNA和疫苗中的应用
US20250041394A1 (en) Immunostimulatory mrna compositions and uses thereof
CN119654141A (zh) 脂质纳米颗粒的组合物
KR20170100033A (ko) 분지형 및 선형 키메라 화합물, 폴리뉴클레오티드, 그것들의 용도 및 제조 방법
JP2026512425A (ja) 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
TW202342753A (zh) 狂犬病核酸疫苗
TWI916817B (zh) 一種針對MICA/B靶點的mRNA腫瘤疫苗
JP2023502925A (ja) 生体内遺伝子治療のためのポリマー封入ウイルスベクター
CA3133151A1 (en) Mrna vaccine
HK40068420A (en) Mrna formulation
HK40068420B (en) Mrna formulation
WO2025153053A1 (en) Composition and methods for inducing antigen specific immunity against kras mutant cells
WO2025189068A1 (en) Mrna-lipid nanoparticle immune modulators against allergic and inflammatory diseases
WO2025240477A1 (en) Methods and materials for enhancing delivery of nucleic acid to cells
WO2024020453A2 (en) Immune system modulators and uses thereof
CN115463210A (zh) 信使核糖核酸疫苗与在诱发抗原特异性免疫反应的方法
TW202602467A (zh) 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
CN121360097A (zh) 一种靶向APCs的脂质纳米颗粒及其应用